ASCO GU 2021: ACE inhibitors associated with superior responses in bladder cancer
A retrospective analysis found that in patients with muscle-invasive bladder cancer (MIBC)...
Feb 16, 2021
A retrospective analysis found that in patients with muscle-invasive bladder cancer (MIBC)...
Feb 16, 2021
Radionuclide therapy directed towards prostate-specific membrane antigen (PSMA) demonstrated promising results in men with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC) [1]. A phase 2 trial compared...
Feb 16, 2021
Tyrosine kinase inhibitor axitinib elicited a 31% response rate in a phase 2 clinical trial that...
Feb 16, 2021
A phase 2 trial demonstrated encouraging outcomes from retroperitoneal lymph node dissection...
Feb 16, 2021
A team of researchers reported that socioeconomic, racial/ethnic, and gender factors influence the...
Feb 16, 2021
MRI is non-inferior to CT for the surveillance of stage 1 testicular seminoma. Over a 6-year...
Feb 16, 2021
Of nearly 80,000,000 USD in funding for bladder cancer research between 2017 and 2019,...
Feb 16, 2021
In CheckMate 9ER, patients with renal cell cancer (RCC) treated with nivolumab plus cabozantinib...
Feb 16, 2021
Determination of human papillomavirus (HPV) status should be done routinely at diagnosis of penile...
Feb 16, 2021
Cure rates for patients with poor- and intermediate-risk metastatic germ cell tumors lag behind...
Feb 16, 2021
Interim data from a clinical trial investigating the efficacy of enfortumab vedotin (EV) on...
Feb 16, 2021
The Institute of Cancer Research in the UK found that the implementation of gemcitabine-platinum...